OmniAb, Inc. (NASDAQ:OABI) CFO Sells 15,526 Shares

OmniAb, Inc. (NASDAQ:OABI - Get Free Report) CFO Kurt A. Gustafson sold 15,526 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total transaction of $50,304.24. Following the completion of the transaction, the chief financial officer now directly owns 212,720 shares of the company's stock, valued at $689,212.80. This trade represents a 6.80 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

OmniAb Stock Down 0.6 %

Shares of OmniAb stock traded down $0.02 during trading on Wednesday, reaching $3.20. The company's stock had a trading volume of 576,116 shares, compared to its average volume of 413,324. OmniAb, Inc. has a 1-year low of $3.16 and a 1-year high of $6.55. The company has a 50-day simple moving average of $3.69 and a two-hundred day simple moving average of $4.07. The company has a market cap of $451.90 million, a price-to-earnings ratio of -5.16 and a beta of -0.10.

Institutional Investors Weigh In On OmniAb

Institutional investors have recently added to or reduced their stakes in the business. Murchinson Ltd. purchased a new position in shares of OmniAb in the 3rd quarter valued at approximately $4,230,000. Dimensional Fund Advisors LP increased its stake in OmniAb by 6.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company's stock valued at $11,296,000 after purchasing an additional 194,835 shares in the last quarter. Rice Hall James & Associates LLC raised its holdings in shares of OmniAb by 6.4% in the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company's stock worth $11,515,000 after buying an additional 163,038 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of OmniAb during the second quarter worth $449,000. Finally, Barclays PLC grew its holdings in shares of OmniAb by 321.5% during the third quarter. Barclays PLC now owns 143,215 shares of the company's stock valued at $606,000 after buying an additional 109,236 shares during the last quarter. Institutional investors and hedge funds own 72.08% of the company's stock.

Analyst Ratings Changes

Several research firms have recently commented on OABI. Benchmark reissued a "buy" rating and issued a $8.00 price target on shares of OmniAb in a research report on Thursday, November 14th. HC Wainwright reiterated a "buy" rating and issued a $11.00 target price on shares of OmniAb in a research note on Thursday, November 14th.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.